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Abbreviations:
3NT

protein bound 3-nitrotyrosine

ARE

antioxidant response element

Ce

cerium

Cat

catalase

EELS

electron energy loss spectroscopy

ENM

engineered nanomaterial

GPx

glutathione peroxidase

GR

glutathione reductase

GSH

reduced glutathione

GSSG

oxidized glutathione

H2O2

hydrogen peroxide

HOS

hierarchical oxidative stress model

HO-1

heme oxygenase -1

Hsp70

heat shock protein 70

LDH

lactate dehydrogenase

MAPK

mitogen-activated protein kinase

Nrf-2

nuclear factor-2

NF-ĸB

nuclear factor kappa B

PC

protein carbonyl

OPT

o-phthaldehyde
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ROS

reactive oxygen species

RNS

reactive nitrogen species

SOD

superoxide dismutase

TEM

transmission electron microscopy
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Abstract
Ceria engineered nanomaterials (ENMs) have very promising commercial and therapeutic
applications. Few reports address the effects of nanoceria in intact mammals, let alone long term
exposure. This knowledge is essential to understand potential therapeutic applications of
nanoceria in relation to its hazard assessment. The current study elucidates oxidative stress
responses in the rat hippocampus 1 and 20 h, and 1, 7, 30, and 90 d following a single systemic
infusion of 30 nm nanoceria. The results are incorporated into a previously described hierarchical
oxidative stress (HOS) model. During the 1-20 h period, increases of the GSSG: GSH ratio and
cytoprotective phase-II antioxidants were observed. During the 1-7 d period, cytoprotective
phase-II antioxidants activities were inhibited with concomitant elevation of protein carbonyl
(PC), 3-nitrotyrosine (3NT), heme oxygenase-1 (HO-1), cytokine IL-1β and the autophagy
marker LC-3AB. At 30 d post ceria infusion, oxidative stress had its major impact. Phase-II
enzyme activities were inhibited; concurrently PC, 3NT, HO-1, and Hsp70 levels were elevated
along with augmentation of IL-1β, pro-apoptotic pro-caspase-3, and LC-3AB levels. This
progress of escalating oxidative stress was reversed at 90 d when phase-II enzyme levels and
activities were restored to normal levels, PC and 3NT levels were reduced to baseline, cytokine
and pro-caspase-3 levels were suppressed, and cellular redox balance was restored in the rat
hippocampus. This study demonstrates that a single administration of nanoceria induced
oxidative stress that escalates to 30 days then terminates, in spite of the previously reported
continued presence of nanoceria in peripheral organs. These results for the first time confirm in
vivo the HOS model of response to ENM previously posited based on in vitro studies and
extends this prior hierarchical oxidative stress model that described three tiers to a 4th tier,
characterized by resolution of the oxidative stress and return to normal conditions.
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1. Introduction
Engineered nanomaterials (ENMs) can be synthesized with different shapes, sizes, composition,
surface coatings, and surface morphology. With versatile physical, chemical and magnetic
properties, ENMs have ever-growing applications in electronics, scientific instruments, sport
equipments, cosmetics, fabrics and their treatments, and as diesel fuel additives, automotive
components, drug delivery systems, and pharmaceuticals (Buzea et al., 2007, Sahu et al., 2013,
Das et al., 2012). Many of these applications are becoming an integral part of our lives. Some
ENMs produce intended outcomes like drug and gene delivery and some produce unintended
consequences through occupational and environmental exposures. Although for many years
researchers were aware of the detrimental health effects of exposure to various ambient ultrafine
particles, it is only recently that scientists are addressing potential health problems of ENM
exposure (Buzea et al., 2007, Yokel et al., 2011). A concern is that insufficient understanding of
ENM toxicity could lead to human health problems and decreased public acceptance.
Ceria (a.k.a. cerium oxide) ENM has numerous current and potential commercial applications
(Hardas et al., 2010). In the integrated circuit manufacturing industry (Feng et al., 2006), ceria is
popularly used as an abrasive due to its abrasiveness. The redox activity of ceria impel its
applications as an oxygen sensor (Molin et al., 2008) and oxygen storage promoters (Yuan et al.,
2009); diesel fuel catalyst facilitating conversion of carbon monoxide to carbon dioxide and
increasing fuel combustion efficiency (Cassee et al., 2011, Park et al., 2007), and as a catalyst for
H2 production from fuel cells (Yuan et al., 2009). Also due to its redox active nature, ceria
reportedly can serve as a reactive oxygen species (ROS) scavenger in biological systems
(Celardo et al., 2011a) where Ce III exhibits antioxidant SOD-like activity (Das et al., 2007,
Karakoti et al., 2009a, Korsvik et al., 2007) while Ce IV has catalase-like behavior (Celardo et
6

al., 2011a, Celardo et al., 2011b, Heckert et al., 2008, Karakoti et al., 2009a, Pirmohamed et al.,
2010). Multiple in vitro studies have documented the ability of ceria to reduce levels of H2O2,
superoxide radical, i-NOS, NF-κB, TNF-α, interleukins, and other ROS endpoints (Celardo et al.,
2011b), to protect against H2O2 induced apoptosis (Chen et al., 2013), and to favorably modulate
cell differentiation and dopamine production (Ciofani et al., 2013). These mechanisms may
explain nanoceria’s demonstrated therapeutic potential for, diabetic cardiomyopathy, diesel
exhaust- and cigarette smoke-induced oxidative stress, radiation therapy side effects, retinal
degradation, cancer, stroke and neurodegenerative disorders (Babu et al., 2010, Celardo et al.,
2011b, Chen et al., 2006, Colon et al., 2010, D'Angelo et al., 2009, Das et al., 2007, Estevez et
al., 2011, Hirst et al., 2009, Niu et al., 2011, Xia et al., 2008). Noteworthy, most of these studies
were conducted in in vitro models of oxidative stress.
Along with evidence of the antioxidant behavior of ceria, evidence of ceria-induced toxicity also
has been accumulating, which makes the true biological behavior of ceria of concern. Ceria
treatments have induced levels of lactate dehydrogenase and the lipid peroxidation productmalonaldehyde, which were associated with decreased cell viability. Ceria decreased reduced
glutathione levels and DNA content (Auffan et al., 2009, Brunner et al., 2006, Lin et al., 2006,
Park et al., 2008). Co-exposure of nanoceria with diesel exhaust increased cytotoxicity and
altered cellular morphology, compared to that seen with diesel exhaust alone (Steiner et al.,
2012). Again noteworthy, most of the reports of ceria-induced toxicity were conducted in nonoxidative stress-stimulated cells. Exposure to ceria was deleterious to Synechocystis PCC6803
and Anabaena CPB4337 (cyanobactreria), Pseudokirchneriella subcapitata (green algae), E.
coli, Daphnia magna, and C. elegans, decreasing growth, fertility, and survival and increasing
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accumulation of lipofuscin and susceptibility to oxidative stress (Rodea-Palomares et al., 2011,
Roh et al., 2010, Thill et al., 2006, Van H et al., 2009, Zeyons et al., 2009).
Due to the variety of its commercial applications, nanoceria was selected for toxicity evaluation
by the NIEHS (NIEHS, 2006) and the OECD Environment Directorate (OECD, 2008, OECD,
2010). Long-term effects of nanoceria in intact animals have not been addressed adequately,
which is required for the safe use of nanoceria in medical applications and to understand the
effects of unintended exposures (Yokel et al., 2012, Yokel et al., 2009). Some studies addressed
the effects of ceria ENM in the intact mammal over a short time, finding granulomatous
inflammation after pulmonary instillation and inhalation in rats (Cho et al., 2010, Srinivas et al.,
2011), reduced myocardial oxidative stress in transgenic mice that displayed ischemic
cardiomyopathy (Niu et al., 2007), reduced retinal vascular lesions after intravitreal injections in
mice (Zhou et al., 2011), mitigated endometriosis lesions that were induced in mice and inhibited
angiogenesis (Chaudhury et al., 2013), pulmonary inflammation and alveolar macrophage
functional changes in rats (Ma et al., 2011) and increased oxidative stress in rat brain and liver
(Hardas et al., 2012, Tseng et al., 2012). Recently some reviews have focused on the need for in
vivo studies examining nanoceria’s biokinetics and long-term toxicity (Cassee et al., 2011,
Celardo et al., 2011b, Yokel et al., 2011). Taking the first initiative, we explored the long term
fate of ceria ENM in an intact animal (Yokel et al., 2012) and found that ceria affects protein
carbonyl (PC) levels in a time-dependent manner. In liver, PC levels were increased after 1, 7
and 30 d, and decreased in the spleen at the same time points. In both organs, PC levels were
significantly reduced 90 d after ceria infusion, in spite of the continuous presence of nanoceria
(Yokel et al., 2012). Two other independent studies also reported the long-term effects of singlelocalized injection of ceria ENM into the retina, where most of nano-ceria was retained even up
8

to 120 d. One of these studies showed no cytotoxicity in rat retina 120 d after a single injection
of nanoceria (Wong et al., 2013). In the second study tubby mice-retinal structure was preserved
up to 49 d and later gradual loss occurred after 80 d, although the structural and functional
improvement remained significantly different than untreated or saline treated (Cai et al., 2012).
This present study is a part of our earlier initiative and the first report addressing the effects of
nanoceria on brain up to 90 days after its peripheral administration.
As pointed out by Xia et al. (Xia et al., 2008), biological systems generally are able to integrate
multiple pathways of toxicity into a limited number of pathological outcomes, including
inflammation, apoptosis, necrosis, fibrosis, hypertrophy, metaplasia and carcinogenesis. The
potential biological toxicity of nanomaterials lies in their much larger surface area-to-volume
ratio and therefore an increased number of atoms available for surface interaction compared to
bulk materials (Nel et al., 2006, Xia et al., 2009). One of the main resultant events of
nanomaterial-biological interaction is generation of reactive oxygen species and oxidative stress
(Buzea et al., 2007, Nel et al., 2006, Xia et al., 2008, Xia et al., 2009). Increased oxidative stress
levels can cause various detrimental cellular effects such as lipid peroxidation, protein alteration,
DNA damage, and disruption of cellular signaling, inflammation, modulation of gene
transcription, apoptosis and necrosis.
The hierarchical oxidative stress (HOS) model (Nel et al., 2006), proposed a three-tiered, timedependent cellular response to ENMs that involved low levels of oxidative stress (Tier 1) leading
to induction of antioxidant and protective responses mediated by the Nrf-2-ARE-signaling
pathway, which modulates Phase-II gene transcription (Chia et al., 2010, Lee et al., 2008, Li et
al., 2004, Speciale et al., 2011, Xiao et al., 2003). At a higher level of oxidative stress (Tier 2),
the cytoprotective properties transcend to pro-inflammatory responses that depend on ROS9

mediated induction of redox-sensitive MAPK and NF-ĸB cascades (Xiao et al., 2003). At the
highest level of oxidative stress (Tier 3), a perturbation of mitochondrial inner membrane
electron transfer and the open/closed status of the mitochondrial permeability transition pore can
lead to cellular apoptosis and cytotoxicity. Using this HOS paradigm, previous studies have
investigated an interlinked range of cellular responses to ambient ultrafine particles in animal
disease models (Gong et al. 2007; Araujo et al. 2008) and to some ENMs, including ceria, in cell
culture models (Xia et al. 2008). The HOS model can be used as a predictive scientific platform
to access ENM biological toxicity (Nel et al., 2006). However, this model, and indeed most
studies of the effects of ENM, has been developed based on in vitro studies.
According to the HOS model (Nel et al., 2006), Tier-1 comprises induction of phase-II
antioxidant enzyme defense response, evoked by elevation of the oxidize glutathione to reduce
glutathione (GSSG: GSH) ratio and consequent activation of the Nrf-2 signaling pathway. This
pathway regulates transcription of phase-II enzymes like glutathione peroxidase (GPx),
glutathione reductase (GR), catalase (Cat), super oxide dismutase (SOD) and heme oxygenase-1
(HO-1) through the antioxidant response element-ARE . Therefore, as representative markers of
Tier 1 response we measured levels and activities of GPx, GR, catalase and SOD and levels of
HO-1. Levels of PC and 3-nitrotyrosine (3NT) give a global estimate of oxidative modification
and damage to cellular proteins by means of ROS and RNS (Beal, 2002, Dalle-Donne et al.,
2003, Hardas et al., 2010) and thus measured for all the time points. An increase in PC or 3NT
level will be an indirect measure of failed antioxidant defense response. If oxidative stress
remained high even after activation of Tier 1 antioxidant response then, the pro-inflammatory
Tier 2 response will be activated through ROS-mediated induction of redox-sensitive MAPK and
NF-ĸB cascades. As a representative marker of Tier 2 response, we measured levels of
10

inflammatory cytokines IL-1β and TNF-α. The escalated unhampered oxidative stress may
further lead to cellular apoptosis and cytotoxicity, i.e., Tier 3 response. Estimation of levels of
pro-caspase-3, which is a precursor for caspase-3, the final executioner of cellular apoptosis,
served as a marker for activation of Tier 3 response. In addition to these markers, levels of heat
shock family protein Hsp70 and autophagy marker LC-3AB were measured at all time points.
Nanoceria is proposed as a therapeutic agent (Cai et al., 2012, Celardo et al., 2011b, Chaudhury
et al., 2013, Ciofani et al., 2013, Karakoti et al., 2009b, Karakoti et al., 2010, Wong et al., 2013),
and thus the effects of its long term exposure need investigation. In the present study, we build
upon our prior investigations of the effects of nanoceria over short- and medium-periods in terms
of brain oxidative stress and other endpoints (Hardas et al., 2010, Hardas et al., 2012, Yokel et
al., 2009) to determine if the HOS model extends to in vivo paradigms and to determine if the
effects of even longer term exposure follow this model. To evaluate the oxidative stress effects
of systemic administration of nanoceria in a time-dependent manner, 30 nm ceria was
administered intravenously in rats. After its infusion, rat hippocampal samples were harvested 1
and 20 h, and 1, 7, 30 and 90 d later, and subjected to selected biochemical assays to assess the
HOS model. The study reveals that the HOS model is valid in vivo through Tier 3, but
biopersistence of ceria leads to a new tier (Tier 4) in which oxidative stress markers return to
normalcy. The results are discussed with respect to the potential use of nanoceria in therapeutic
settings.
2. Materials and Methods
2.1. Nanomaterial synthesis and characterization
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Thirty nm nominal diameter citrate-capped nanoceria were synthesized and extensively
characterized in house, as described (Dan et al., 2012, Yokel et al., 2013). The nanoceria were
cubic (Figure 1) with a BET surface area of 15 m2/kg. The average (and S.D. diameter) of the
primary particles determined by TEM was 31.2 (17.1) nm. When dispersed in water a bimodal
distribution was seen, with an average size at 41 nm (representing 100% of the number and 36%
of the volume of the nanoceria) and 273 nm (representing the remaining 64%). A TEM image of
the particles and results of dynamic light scattering determination have been reported (Yokel et
al., 2012, Yokel et al., 2013). The zeta potential of - 56 ± 8 mV at pH ~ 7.3, and ~ 18% citrate
surface coated. It was washed and had a free Ce content of << 1%. It was prepared as a ~ 5%
dispersion in water for intravenous infusion (Yokel et al., 2013). Prior to and 90 days following
administration, the nanoceria was analyzed using electron energy loss spectroscopy (EELS) to
determine its M4/M5 ratio as a measure of its original oxidative signature EELS measurements
were performed using the 2 Angstrom probe, an alpha of 20 mrad, and a beta of 6 mrad, to
estimate the Ce(III) versus Ce IV oxidation states from the cerium M4 (~ 900 eV) and M5 (~ 883
eV) edges and M4/M5 ratio.
2.2. Animals
This study reports results from 66 male Sprague Dawley rats, weighing 323 ± 36 g (mean ± SD)
(~ 70 days old). The rats were obtained from Harlan, Indianapolis, IN. They were housed
individually throughout the study in the University of Kentucky Division of Laboratory Animal
Resources facility under a 12:12 h light: dark cycle at 70 ± 8°F and 30 to 70% humidity. The rats
had free access to 2018 Harlan diet and reverse osmosis water. Animal work was approved by
the University of Kentucky Institutional Animal Care and Use Committee. The research was
conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology
12

(http://www.toxicology.org/ai/air/air6.asp). Rats were prepared for i.v. ceria (or water, the ENM
vehicle) and 1.8% sodium chloride (saline) infusion by surgical implantation of cannula into
each femoral vein, that terminated in the vena cava. A day or two later the nanoceria (or vehicle)
was infused. The dose of nanoceria administered to the rats as a 1 h infusion was found to be 87
mg ceria (70 mg cerium)/kg, determined by ICP-MS analysis of the dosing dispersion. Rats
tolerated the ceria infusion well. Daily cage-side observations revealed no adverse effects (Yokel
et al., 2012). There were 5 controls and 5 ceria-treated rats in the 1 and 20 h groups, 3 controls
and 3 treated rats in each of the 1 and 7 day groups, 10 controls and 11 treated rats in the 30 day
group, and 6 controls and 7 treated rats terminated 90 days after the single nanoceria
administration. To determine ceria levels, brain, liver and venous blood samples were collected
when the rats were terminated.
2.3 Cerium quantification
Tissue and blood samples were microwave digested in digestion vessels by nitric acid and
hydrogen peroxide. The samples were diluted, terbium was added as an internal standard, and
analyzed compared to cerium standards by ICP-MS. The methods are described in the
Supplementary Information of (Yokel et al., 2013). Samples from control rats that did not
receive nanoceria, acid blanks (digestion tubes with no tissue sample but otherwise processed
identically), and analysis of duplicate samples and a duplicate sample spiked with a known
amount of cerium included with every 20 samples were concurrently processed. The cerium
concentration in blanks and > 80% of the samples from the control rats was below the instrument
detection limit (0.02 to 0.03 μg/l) (Yokel et al., 2012).
2.4 Biochemical assays for oxidative stress assessment
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Sample preparations for all of the biochemical assays were carried out as previously described
(Hardas et al., 2010, Hardas et al., 2012) unless described otherwise. A small portion of unhomogenized frozen hippocampal tissue from each rat was saved for GSH assay. The remaining
hippocampal sample from each rat was thawed and homogenized using a manual Wheaton glass
homogenizer in Media 1 (300-500 µL) buffer containing: 0.32 M sucrose, 0.10 mM Tris-HCl,
0.10 mM MgCl2, 0.08 mM EDTA, 10 µg/ml leupeptin, 0.5 µg/ml pepstatin, 11.5 µg/ml aprotinin
and PMSF 40 µg/ml; pH 8.0. After sample homogenization, protein concentration was
determined by the Pierce bicinchoninic acid (BCA) assay.
2.4.1

The oxidize: reduce glutathione (GSSG: GSH) ratio

GSH and GSSG levels were measured simultaneously in un-treated tissue using the Hissin and
Hiff fluorescence spectroscopic method (Hissin et al., 1976). A small amount (in mgs) of freshly
thawed hippocampal tissue was rapidly weighed, homogenized with metaphosphoric acid (25%)
1:4 w/v and sodium phosphate (0.1 M) – ethylenediaminetetraacetic acid (0.005 M) buffer (pH
8) 1:15 w/v and then centrifuged. For GSH levels, an aliquot of supernatant was further diluted
with phosphate buffer and then incubated with OPT, before determination of fluorescence (λex
350 nm and λem 420 nm). For GSSG levels equal volumes of supernatant and N-ethylmaleimide
(0.04 M) were incubated for 30 min and then diluted with sodium hydroxide (0.1 N), before
assaying with OPT. The GSSG: GSH ratio for each sample was calculated by comparing the
fluorescence values from each assay to their respective calibration curves. The final values were
expressed as % of mean ± SEM of treated vs. control samples.
2.4.2

PC and 3NT levels
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Global levels of the modified protein markers, PC and 3NT were measured employing the slot
blot technique (Hardas et al., 2010, Sultana et al., 2008). For measurement of PC levels, each
homogenized hippocampal sample (5 µL) was derivatized at room temperature by incubation
with 5 µL of 12% SDS and 10 µL of 10 mM 2, 4-dinitrophenylhydrazine solution in 2N HCl for
20 min. After 20 min the sample was neutralized by adding 7.5 µL of neutralization buffer
supplied with the OxyBlot Protein Oxidation Detection Kit (Chemicon International, Millipore,
Temecula, CA). Further, a derivatized sample was diluted with phosphate saline buffer (10 mM,
pH 8 with 0.88% NaCl) to obtain a final concentration of 1 µg/ml. A 250 µL aliquot from each
diluted sample was loaded in duplicate onto a nitrocellulose membrane under vacuum pressure
using a BioRad slot blot apparatus (BioRad, Hercules, CA). The resultant nitrocellulose
membrane was incubated with anti-PC rabbit antibody (5: 10,000, Chemicon International,
Millipore, Temecula, CA) and subsequently with anti-rabbit alkaline phosphatase secondary
antibody (2.5: 10,000, Sigma Aldrich, St. Louis, MO). For 3NT levels each homogenized
hippocampal sample (5 µL) was incubated at RT with 5 µL of 12% SDS and 10 µL of Laemmli
buffer (0.125 M Tris pH 6.8, 4% v/v SDS, 20% v/v glycerol) for 20 min followed by incubation
with anti-3NT rabbit antibody (8: 10,000, Sigma Aldrich, St. Louis, MO) and subsequently with
anti-rabbit alkaline phosphatase secondary antibody (2.5: 10,000, Sigma Aldrich, St. Louis,
MO). Protein-antibody conjugates were detected using an enhanced colorimetric method
(Sultana et al., 2008).
2.4.3

Antioxidant, HSP, and cytokine protein levels

The levels of phase-II antioxidant proteins GR, GPx, manganese-SOD, and Cat, heat shock
proteins HO-1 and Hsp70, cytokines TNF-α and IL-1β, apoptosis marker pro-caspase-3, and
autophagy marker LC-3AB, were measured using immunoblotting, i.e., Western blot techniques
15

as described (Hardas et al., 2010, Sultana et al., 2008). In brief, 75 µg protein from each
homogenized hippocampal sample was loaded and separated on SDS-PAGE alongside its
respective control. The separated proteins were transferred from polyacrylamide gels to
nitrocellulose membranes. The resultant nitrocellulose membranes with protein bound to them
were probed separately with primary antibodies raised against specific proteins; polyclonal GR
(Abcam, Cambridge, MA), monoclonal GPx (Epitomics, Burlingame, CA), monoclonal
manganese-SOD (Epitomics, Burlingame, CA), polyclonal Cat (Epitomics, Burlingame, CA),
monoclonal HO-1 (Epitomics, Burlingame, CA), polyclonal Hsp70 (Cell signaling, Boston,
MA), polyclonal TNF-α (Abcam, Cambridge, MA), polyclonal IL-1β (Novus Biologicals,
Littleton, CO), polyclonal pro-caspase-3 (Calbiochem, EMD Millipore, Billerica, MA), and
monoclonal LC3AB (Epitomics, Burlingame, CA), each with ~1:1000 dilution. Subsequently
each membrane was incubated with a secondary antibody raised against IgG antibody (2.5:
10,000, Sigma Aldrich, St. Louis, MO). Actin was used as a loading control for each protein
band. The intensities of protein-antibody conjugates were detected and used for comparison.
2.4.4

Antioxidant enzyme activities

The activities of GPx, GR, SOD and Cat antioxidant enzymes were determined using ready-touse specific enzyme assay kits from Cayman Chemical Company (Ann Arbor, MI), according to
the manufacturer’s directions as described previously (Hardas et al., 2010). Briefly, 10-20 µg of
homogenized sample was loaded along with standards provided on a 96-well plate and mixed
with the assay buffer provided in the kit. Along with other particular assay related specific
reagents, reaction initiator was added to the mixture, such as cumene hydroperoxide for the GPx
assay, NADPH for the GR assay, hydrogen peroxide for the Cat assay, and xanthine oxidase for
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the SOD assay. The change in absorbance of the substrate, monitored spectrophometrically, was
correlated with the change in concentration of the substrate and the enzyme activity.
2.5 Data and statistical analysis
Grubb’s test was used to identify outliers in the results from biochemical assays performed for
oxidative stress assessment. Hippocampal samples obtained from rats that received saline in both
cannulae were used as controls. As described in the Animals section, each time point had its
respective control rats. The histograms in the figures are percent of control calculated from ceriatreated samples normalized to their respective time point controls and expressed as % control
mean ± SEM. Statistical difference was estimated using Students unpaired t-test comparing
percent of treated to control values, accepted at *p <0.05, ξp <0.01 and Θp <0.001.
3.

Results

3.1. Ceria concentration in selected sites
The nanoceria (Figure 1) were rapidly cleared from circulating blood. One site of its
accumulation was the liver. Very little ceria was in the brain, much of which could be accounted
for by the blood within the vessels perfusing the brain (Table 1). Blood cerium rose sharply in
the rats terminated 90 days after nanoceria administration. This may be due to the partial
dissolution of nanoceria particles observed in the liver at that time (unpublished findings) and the
very low rate of cerium excretion (unpublished findings) consistent with the long half-life of
cerium in mammals, assumed to be 3500 days (Ishigure, 1999).
3.2 EELS Results.
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Since liver accumulated nanoceria while brain did not, EELS data were collected on nanoceria in
liver 90 days after nanoceria administration. The EELS results showed 90-day nanoceria in the
liver, similar to as-prepared nanoceria, to have a decreased oxygen vacancy and enhanced Ce III
at its outer rim (surface layer), while the central (core) region of the particles are in the Ce IV
state (~stoichiometric CeO2). This enriched Ce III effect at the surface was observed in the EELS
spectrum as the height of the narrow intense peaks at the cerium M5 and M4 edges (~883 and
900 eV) with intensity of M5 greater than that of M4. Two representative EELS spectra from the
exterior surface and core zone of the ceria show the enrichment of Ce III at the particle rim
(surface layer) (Graham et al., 2013) (Figure 2).
3.2.Oxidative Stress Indices
3.2.1. The GSSG: GSH ratio, an indicator of oxidative stress
GSH, an important endogenous antioxidant, is used by GPx to reduce peroxides and peroxyl free
radicals. GSSG is reduced back to GSH by GR. The GSSG: GSH ratio is a primary marker for
the cellular redox state. An increase in the GSSG: GSH ratio suggests increased oxidative stress.
After systemic administration of 30 nm ceria, the GSSG: GSH ratio was significantly increased
in the hippocampus from 1 h to 30 d, indicating elevated oxidative stress, while a decreased
GSSG: GSH ratio was observed at 90 d, implying restoration of cellular redox status. These
glutathione-related data are presented and discussed in detail in a separate paper recently
submitted (Graham et al., 2013).

3.2.2. Induction of Tier 1 oxidative stress responses 1 and 20 h after nanoceria infusion: An
increase in PC, 3NT and HO-1 levels was inversely related to phase II antioxidant enzyme
activities
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Phase II antioxidant enzymes such as GPx, GR, Cat and SOD are markers for the Tier 1
oxidative stress response (per the HOS model). Both levels as well as activities of GPx and Cat
were induced 1 and 20 h after nanoceria exposure (Figures 3a and b). While GPx and Cat levels
were elevated 30 days after nanoceria infusion, their enzyme activities were significantly
decreased from 1-30 d (Figures 3a and b). Inhibition in enzyme activity in spite of elevated
enzyme levels may imply oxidative modification of enzyme proteins. However, 90 d after
nanoceria dosing the levels and activities of phase-II enzymes had generally returned to control
levels, except Cat activity, which was still elevated (Figures 3a and b). The GR level was
decreased after 20 d and increased after 30 d, while GR-activity remained unchanged at all time
points except after 30 d when it was significantly elevated (data not shown). Manganese-SOD
levels and activity remained unaffected by the nanoceria (data not shown).
Changes in PC and 3NT levels showed a reverse trend compared to changes in GPx and Cat
activities. The decrease in PC and 3NT levels at earlier time points (1 and 20 h) and increase 1, 7
and 30 d after nanoceria infusion (Figure 4), suggest a failing of the Tier 1 antioxidant defense
response at later time points. Along with PC and 3NT levels, the level of oxidative stressinduced HO-1 and Hsp 70 also were increased (Figure 5), although Hsp 70 showed few temporal
variations, except a significant decrease at 20 h and a significant increase at 30 d (Figure 5).
3.2.3. Induction of Tier 2 oxidative stress response 1, 7, and 30 d after nanoceria infusion
Levels of the inflammatory cytokine and Tier 2 marker (IL-1β) did not show any change at the
earlier time points (1 and 20 h), but their levels increased 1 and 30 d after nanoceria dosing
(Figure 6). The modulation of IL-1β levels was in agreement with the change in PC, 3NT and
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HO-1 levels, whereas inversely related to GPx and Cat activity. Cytokine TNF-α level decreased
at 1 h but did not increase after any time point, and changes were not significant (Figure 6).
3.2.4. Induction of Tier 3 oxidative stress response 30 d after nanoceria treatment
Levels of the pro-apoptosis and Tier-3 marker, pro-caspase-3, were increased at 30 d (Figure 7).
Elevated levels of the pro-apoptosis marker were temporally concurrent with increased PC, 3NT,
HO-1 and IL-1β levels as well as decreased phase-II enzyme activities 30 d after nanoceria
treatment.
3.2.5. An autophagy marker appears at 7 d, 30 d and at 90 d [the 90 day result is below
control]
Escalated oxidative stress can activate autophagy responses (Gottlieb et al., 2010, Hariharan et
al., 2011, Marambio et al., 2010) to recycle or restore altered macromolecules and organelles.
Oxidatively-modified proteins are selectively removed by chaperon-mediated autophagy
(Kaushik et al., 2006, Kiffin et al., 2004). Levels of the autophagy marker LC-3AB, were
concomitantly induced with induction of the GSSG: GSH ratio, PC, and 3NT levels at 7 and 30 d
along with an increase in Hsp70 levels at 30 d. On the other hand at 90 d, LC-3AB levels went
down as the GSSG: GSH ratio returned to normalcy and PC and 3NT levels were suppressed
(Figure 8). Concurrently increased LC-3AB and Hsp70 could potentially activate a chaperonemediated autophagy process or Tier-4 response, which could lead to clearance of oxidativelymodified proteins, enzymes, and other biomolecules and therefore restoring the cellular redox
balance at 90 d.
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4. Discussion
Studies on nanoceria have revealed both pro- and anti-oxidant behavior. A review summarizes
the evidence available on free radical scavenging ability of nanoceria under pre-induced
oxidative stress conditions (Karakoti et al., 2009a). However, 30 nm ceria was shown to induce
ROS in BEAS-2B cells in culture after 24 h incubation in a dose-dependent manner in the
absence of any external ROS source. In the same experiment nanoceria decreased cell viability in
a size-independent manner (Park et al., 2008). Our previous studies with 5 nm nanoceria showed
the absence of oxidative stress effects in rat brain 1 and 20 h post infusion (Hardas et al., 2010)
and pro-oxidant effects in rat brain and liver 30 d after infusion (Hardas et al., 2012, Tseng et al.,
2012). Another study with 30 nm nanoceria reported induction of PC levels in liver and
reduction in spleen in a time-dependent manner from 1 to 30 d (Yokel et al., 2012). In the same
study, PC levels were found to be significantly reduced 90 d after nanoceria in both liver and
spleen. The present work is an extension of our previous work with nanoceria. We demonstrated
that a single 30 nm nanoceria infusion, which does not lead to any appreciable nanoceria in brain
(Yokel et al., 2012) and in table 1 of this report, induced an oxidative stress response and
secondary oxidative stimulus in a time-dependent manner in the hippocampus.
Effects of ceria on oxidative stress parameters are robust. The changes in oxidative stress
parameters that we saw are on the order of what we have reported in neurodegenerative disorders
like Alzheimer disease (Sultana et al., 2009, Sultana et al., 2006, Butterfield et al., 2013), putting
the severity of the biological responses in this study in perspective. A positive control was not
included because at the time we initiated this study we could not find a relevant metal-based
ENM that had demonstrated effects on rodent brain oxidative stress endpoints that we felt was an
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appropriate positive control. The current work is also the first comprehensive study that validates
the HOS model with an in vivo toxicological evaluation of an ENM (Nel et al., 2006).
Furthermore, our results revealed that biopersistence of nanoceria in vivo leads to a new tier (Tier
4), an extension of the HOS model, in which oxidative stress markers return to normalcy.
Various oxidative stress response pathways can be initiated depending on the severity of
incidences such as oxidative insult, free radical generation, or decline in cellular redox state
mediated by external or internal stimuli (Chia et al., 2010, Lee et al., 2008, Speciale et al., 2011).
In the current study, the systemic, onetime infusion of 30 nm nanoceria demonstrated aspects of
all three tiers of the HOS model in the rat hippocampus. The nanoceria treatment elevated the
GSSG: GSH ratio at early time points (1 and 20 h), which would have induced the Tier 1 defense
response. As a result, GPx and Cat levels as well as their activities were increased and PC and
3NT levels were suppressed, which illustrates cytoprotection (Figure 9a and b). However, the
Tier 1 defense appears to not hold up against the oxidative stress induced by biopersistent
nanoceria, as the GSSG: GSH ratio was increased after 1 d and remained elevated through the
30th day after nanoceria administration. Inflammatory cytokine IL-1β levels were also induced 1
and 30 d after nanoceria infusion. Thus with activation of inflammatory cytokines, a.k.a the Tier
2 response after 1 d, PC and 3NT levels were also increased (Figure 9a and b). The oxidative
stress inducible heat shock family proteins (HSP) HO-1 and Hsp70 levels were concomitantly
induced with PC and 3NT levels 1, 7 and 30 d after ceria infusion. Usually, such stress-induced
molecules or proteins not only exhibit cytoprotection against immediate threat but also reinforce
the cellular defense against possible future menaces (Morse et al., 2005). HO-1 also is a phase-II
antioxidant enzyme, and nitrosative stress has been associated with its induction (Calabrese et
al., 2002, Ghosh et al., 2011, Mancuso et al., 2009, Poon et al., 2004). In the case of HO-1, while
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it removes toxic heme, it also produces biliverdin, a precursor for the antioxidant bilirubin
(Barone et al., 2009, Mancuso et al., 2012). HO-1 has been shown to be neuroprotective against
UV-light, lipopolysaccharide, heme, and various oxidative stress stimuli, especially against
nitrosative stress (Calabrese et al., 2007, Calabrese et al., 2002, Calabrese et al., 2004, Ghosh et
al., 2011, Mancuso et al., 1999, Poon et al., 2004). Hsp70 acts as a chaperone for other proteins
by assisting protein folding and protein transport across membranes within the cell (Brown,
2007, Poon et al., 2004, Yenari et al., 1999). Additionally Hsp70 helps to prevent protein
aggregation induced by oxidative modification as well as aid transport for the clearance
mechanism of unfolded, aggregated proteins (Mayer et al., 2005, Young et al., 2003, Hartl et al.,
2002, Calabrese et al., 2004, Calabrese et al., 2007). However, in spite of induction of
cytoprotective HSP levels, downstream consequences of initiation of Tier 2-pro-inflammatory
cytokine responses and elevated GSSG:GSH ratio lead to activation of the pro-apoptotic
signaling cascade (Shakibaei et al., 2007, Nesic et al., 2004), a.k.a the Tier 3 response observed
after 30 d. The pro-caspase-3 levels were induced, concurrent with elevated PC, 3NT and IL-1β
levels (Figure 9a and b). Pro-caspase-3 protein is the precursor for caspase-3, and its levels were
measured to estimate the possibility of activation of caspase-3, the final executioner of cellular
apoptosis.
Simply extending the trajectory of the Tier 1 to Tier 3 of the HOS model, we were expecting to
find profound deleterious effects on cellular redox status after 90 d. But quite to the contrary, we
believe for the first time we have demonstrated that the GSSG: GSH ratio was restored back to
control levels as phase-II antioxidant levels and activities (except Cat activity was increased),
PC, 3NT, HSP levels were returned to normalcy after 90 d as shown in Figure 9a and b. In
brief, after 90 d, there was no sign of oxidative stress in the hippocampus, let alone damage
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caused by oxidative stress. As elevated oxidative stress can negatively affect cellular assembly
leading to misfolded or damaged proteins and organelles and protein aggregation, the efficient
removal of such damaged cellular material from the cytoplasm is essential for cell survival and
adaptation. Cells can avoid accumulation of potentially toxic misfolded protein aggregates by
accessing an array of mechanisms; one such mechanism is the lysosomal-degradation autophagy
process (Ryhänen et al., 2009). The autophagy marker LC-3AB showed a increasing trend from
7 to 30 d, coinciding with the markers of escalating oxidative stress (Figure 9a). Among the three
types of autophagy mechanisms, chaperone-mediated autophagy was shown to selectively clear
out oxidatively-modified proteins from the cytoplasm during aging and age-related disorders in
mammalian cells (Kaushik et al., 2006, Kiffin et al., 2004, Ryhänen et al., 2009). Hsp70 assists
in chaperone-mediated autophagy (Dice, 2007, Ryhänen et al., 2009, Witt, 2010). Consistent
with the findings of LC-3AB, Hsp70 also showed an increasing trend with accelerating oxidative
stress from 1 to 30 d (Figure 9a and b). Hsp70 is known to protect cells from endoplasmic
reticulum-stress induced apoptosis (Gupta et al., 2010). Hsp70 and autophagy can play a
significant role against the progression of neurodegenerative diseases (Wilhelmus et al., 2007,
Witt, 2010) in which Hsp70 modulates protein aggregation as well as removes hazardous protein
aggregates (Poon et al., 2004). Thus, restoration of the redox balance observed after 90 d
following ceria administration might have been the downstream consequence of activation of the
autophagy process (7 d) and/or induction of Hsp70 (30 d), which might have cleared damaged
macromolecules and organelles, and aided in cell adaptation. In the field of biology and
medicine, cellular cleansing is known as hormesis, defined as “…an adaptive response of cells
and organisms to a moderate (usually intermittent) stress” (Mattson, 2008). Autophagy may
increase organismal fitness by obstructing cell death and increasing hormesis (Rubinsztein et al.,
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2011), whereas induction of HSPs can be an effector to promote hormesis-mediated therapy in
neurodegenerative conditions (Calabrese et al., 2010a, Calabrese et al., 2010b). Although the
preponderance of evidence of this study supports the notion that the recovery to the normal state
occurs after a lengthy period, that we term Tier 4, recovery is potentially possible at every tier
(Halliwell et al., 2007). Therefore, based on our current findings, we propose that the restoration
of the normal redox status of the hippocampus 90 d after nanoceria infusion is an extension to
the original hierarchical oxidative stress model, as a Tier 4 response (Figure 9b).
The findings presented in this report, although unexpected, are consistent with the fate of
nanoceria in the mammal. The percentage of nanoceria absorbed from the lungs and
gastrointestinal tract is very low (Geraets et al., 2012, He et al., 2010, Hirst et al., 2013, Park et
al., 2009), requiring systemic or local administration to achieve appreciable concentrations in
organs. Nanoceria is rapidly cleared from blood into mononuclear phagocyte organs, as are most
nanoparticles that are not surface-coated to target specific sites (Glazer et al., 2011, Pouliquen et
al., 1991, Riviere, 2009, Yokel et al., 2012). There is very little elimination of nanoceria from the
mammal (Pairon et al., 1995, Yokel et al., 2012). Although quite insoluble (He et al., 2010), we
have seen some dissolution of nanoceria in the liver 90 days after its intravenous administration,
that presumably released cerium ion, some of which appears to have resulted in formation of
ultra-small nanoceria particles in the liver that inherently have, due to their small size, a greater
percentage of Ce III on their surface, the valence state that enables the antioxidant effects of
nanoceria (Graham et al., 2013). This biotransformation is presumably related to the temporal
change in the oxidative stress markers in the brain. Nanoceria is being investigated by many as a
potential antioxidant, anti-inflammatory therapeutic (Das et al, 2013l Wason and Zhao, 2013).
As this current study shows, nanoceria’s effects on oxidant stress endpoints change over time. It
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is essential to understand the pro- and/or anti-oxidant effects of nanoceria during its very
prolonged residence in mammals, including humans, to know if nanoceria produces beneficial or
detrimental effects, particularly if it is used as a therapeutic to reduce detrimental effects of
inflammatory diseases. Further work assessing the long-term effects of nanoceria in models of
short- and long-duration inflammatory disease is necessary.
5. Conclusion
Although it is true that many times toxicity can be followed by recovery, however depending on
the severity of the insult, recovery processes may or may not take place. Furthermore, there is no
literature evidence on recovery response after in vivo NP particle toxicity, and this is certainly
the first in vivo study that reports the time dependent ENM toxicity followed by recovery. The
significance of the current study is twofold: a) this is the first demonstration of the hierarchical
oxidative stress model in brain or in vivo, and b) this study enabled us to expand the three-tiered
HOS model to Tier 4. However, there is a need to follow and test the extended hierarchical
oxidative stress model with various types and sizes of ENMs vs. time after exposure, to get a
better understanding of oxidative stress effects induced by ENMs. The findings of this study
reassert the importance of oxidative stress effects of bio persistent ceria ENM and its
implications to its proposed medical or pharmaceutical applications. We believe that the current
study will serve as a basis for beginning this large task.
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Figure legends
Figure 1 Nanoceria imaged using high-resolution-TEM. The ceria were dispersed on a carbon
film.
Figure 2 Schematic illustration for 30 nm CeO2 particle cross section: areas of enriched Ce III
correspond to CeO2-x (oxygen vacancies in surface layer). EELS analyses (performed with
nanoprobe ~1 nm) show oxidation state variations for the surface and the bulk. Bulk ceria show
Ce M5/M4 peaks with M5<M4 (M4 line stronger than M5) and typical Ce IV features identified as
satellite peaks (dashed circles). Surface layer shows weaker M4 line (M5>M4, i.e., Ce III > Ce
IV) and no satellite peaks.
Figure 3 GPx and Cat levels-(a) and activities-(b) bottom in rat hippocampus after 30 nm
nanoceria infusion.
Figure 4 PC and 3NT levels in rat hippocampus after 30 nm nanoceria infusion.
Figure 5 HO-1 and Hsp70 protein levels in rat hippocampus after 30 nm nanoceria infusion.
Figure 6 IL-1β and TNF-α levels in rat hippocampus after 30 nm nanoceria infusion.
Figure 7 Pro-caspase-3levels in rat hippocampus after 30 nm nanoceria infusion.
Figure 8 LC-3AB levels in rat hippocampus after 30 nm nanoceria infusion.
Figure 9 This figure summarizes the findings of the current study and their correlation with the
HOS model with extension (Tier 4) based on rat hippocampal oxidative stress responses
observed from 1 h to 90 d after a single systemic infusion of 30 nm ceria ENM. Fig. 9a) Tabular
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representation of quantitative changes in oxidative stress parameters as a function of time, Fig.
9b) schematic representation of mechanisms of nanoceria-induced oxidative stress and toxicity
as a function of changes in oxidative stress markers (Note: the x-axis in this figure is not drawn
to scale). A single infusion of 30 nm nanoceria increased the GSSG: GSH ratio, which induced a
Tier-1 response during 1-20 h, leading to elevation of phase-II antioxidant enzymes GPx and Cat
levels and activities through activation of the Nrf-2 signaling pathway. The biopersistent
nanoceria-induced oxidative stress maintained elevated levels of the GSSG: GSH ratio after 1 d,
GPx and Cat activities were inhibited and PC, 3NT, HO-1, and Hsp70 levels were elevated.
Consequently, the HOS model Tier 2 response was evoked by activation of NF-ĸB pathways
leading to induction of inflammatory cytokine IL-1β levels at 1 d. As oxidative stress persisted
the major impact on cellular homeostasis was observed at 30 d. The Tier-3 response was
activated, indicated by augmentation in IL-1β and pro-apoptotic pro-caspase-3 levels observed
30 d after ceria treatment. The progression of oxidative stress was reversed as the GSSG: GSH
ratio, GPx activity, and HO-1, Hsp70, IL-1β, and pro-caspase-3 levels returned to normalcy at
90 d. In order to better understand the return to normalcy of the oxidative stress response, the
levels of the autophagy marker LC-3AB were measured. LC-3AB levels showed an increase 7
and 30 d after nanoceria infusion along with an increasing trend in Hsp70 levels. Concomitant
changes in LC-3AB and Hsp70 suggest the possibility of activation of a chaperone mediatedautophagy process, which conceivably may have helped in restoration of redox balance at 90 d
and cellular adaptation to 30 nm nanoceria mediated-oxidative stress injury. Therefore,
mitigation of the oxidative stress response observed at 90 d is proposed as Tier 4, an extension to
the HOS three-tiered model.
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Table and Figures
Table 1 Cerium in blood, brain, and liver, expressed as a percent of the nanoceria dosea

Blood

Brain

Liver

1h

0.01 ± 0.01

0.0003 ± 0.0002

40 ± 7

20-24 h

0.20 ± 0.11

0.018 ± 0.016

33 ± 9

7d

0.0043 ± 0.0002

0.00035 ± 0.00002

37 ± 7

30 d

0.0046 ± 0.0047

0.00064 ± 0.00066

30 ± 11

90 d

3.81 ± 2.67

0.001 ± 0.001

21 ± 8

a

Blood values are based on the reference volume of blood in the rat (7% of body weight). Brain

and liver values were calculated from the ceria concentration x organ weight/nanoceria dose.

37

Figure 1

38

Figure 2

39

Figure 3a and b

3a

3b

40

Figure 4

41

Figure 5

42

Figure 6

43

Figure 7

44

Figure 8

45

Figure 9a and b

9a

9b

46

